Boris,
I think three factors are at play here, at least in the immediate-term.
1. The Kevin Sellers Effect, as detailed by Alan at the AGM:
"When you bring together the supply agreements that we have already signed, and use conservative industry assumptions, we can look forward to the production and supply of several hundred million units annually across all out platforms. We expect that our wearable injector business alone is on the pathway to generating over a billion dollars of annual revenue. Now, combine that with the recurring predictable nature of our revenue streams, the 10 and 15 year length of our Supply Agreements, and blended target operating margins north of 40%, and you might see the commercial momentum of our business, and the value the we have already built in within our company. I expect that this will soon be better understood by the capital markets."
Less than a month later Kevin Sellers joined Unilife.
From the appointment announcement:
"One initial area of focus will be utilising his significant experience in investor relations to further strengthen relationships with our shareholders and the investing community."
2. Market expectation/anticipation about the appointment of a new CFO.
Alan, in response to a question at the AGM:
"We are on a trajectory of growth, rapid enormous growth over the next four or five years, and we are being very particular about the kind of senior executive we want...I know exactly the type of person we are looking for that's going to add real value driving the company...with commercial experience that can help drive us to that next stage.
3. Further market expectation of additional significant long-term Supply Agreements from the burgeoning pipeline.
No real need to detail this. It's all in the various announcements. Really just a question of who will it be, and when?
Soon, I'd suggest.
Then, who, or what, will be next?
Expand
